Search

Your search keyword '"Candelaresi, Paolo"' showing total 7 results
Start Over Author "Candelaresi, Paolo" Publisher sage publications
7 results on '"Candelaresi, Paolo"'

1. Baseline clinical and neuroradiological predictors of outcome in patients with large ischemic core undergoing mechanical thrombectomy: a retrospective multicenter study

Author

Alexandre, Andrea, primary, Monforte, Mauro, additional, Brunetti, Valerio, additional, Scarcia, Luca, additional, Cirillo, Luigi, additional, Zini, Andrea, additional, Scala, Irene, additional, Nardelli, Vincenzo, additional, Arbia, Francesco, additional, Arbia, Giuseppe, additional, Frisullo, Giovanni, additional, Kalsoum, Erwah, additional, Camilli, Arianna, additional, De Leoni, Davide, additional, Francesca, Colò, additional, Abruzzese, Serena, additional, Piano, Mariangela, additional, Rollo, Claudia, additional, Macera, Antonio, additional, Ruggiero, Maria, additional, Lafe, Elvis, additional, Gabrieli, Joseph Domenico, additional, Cester, Giacomo, additional, Limbucci, Nicola, additional, Arba, Francesco, additional, Ferretti, Simone, additional, Da Ros, Valerio, additional, Bellini, Luigi, additional, Salsano, Giancarlo, additional, Mavilio, Nicola, additional, Russo, Riccardo, additional, Bergui, Mauro, additional, Caragliano, Antonio Armando, additional, Vinci, Sergio Lucio, additional, Romano, Daniele Giuseppe, additional, Frauenfelder, Giulia, additional, Semeraro, Vittorio, additional, Porzia, Ganimede Maria, additional, Lozupone, Emilio, additional, Romi, Andrea, additional, Cavallini, Anna, additional, Milonia, Luca, additional, Muto, Massimo, additional, Candelaresi, Paolo, additional, Calabresi, Paolo, additional, Pedicelli, Alessandro, additional, and Broccolini, Aldobrando, additional

Published
2024
Full Text
View/download PDF

2. Sex differences in cerebral venous sinus thrombosis after adenoviral vaccination against COVID-19

Author

Scutelnic, Adrian, primary, van de Munckhof, Anita, additional, Krzywicka, Katarzyna, additional, van Kammen, Mayte Sánchez, additional, Lindgren, Erik, additional, Cordonnier, Charlotte, additional, Kleinig, Timothy J, additional, Field, Thalia S, additional, Poli, Sven, additional, Lemmens, Robin, additional, Middeldorp, Saskia, additional, Aaron, Sanjith, additional, Borhani-Haghighi, Afshin, additional, Arauz, Antonio, additional, Kremer Hovinga, Johanna A, additional, Günther, Albrecht, additional, Putaala, Jukka, additional, Wasay, Mohammad, additional, Conforto, Adriana Bastos, additional, de Sousa, Diana Aguiar, additional, Jood, Katarina, additional, Tatlisumak, Turgut, additional, Ferro, José M, additional, Coutinho, Jonathan M, additional, Arnold, Marcel, additional, Heldner, Mirjam R, additional, Antonenko, Kateryna, additional, Mbroh, Joshua, additional, Brodard, Justine, additional, Hooshmandi, Etrat, additional, Dizonno, Vanessa, additional, Devroye, Annemie, additional, Ciccone, Alfonso, additional, Wittstock, Matthias, additional, Zimmermann, Julian, additional, Bode, Felix J., additional, Skjelland, Mona, additional, Duan, Jiangang, additional, Hiltunen, Sini, additional, Zuurbier, Susanna M., additional, Petruzzellis, Marco, additional, Sharma, Aarti R., additional, Ghoreishi, Abdoreza, additional, Elkady, Ahmed, additional, Negro, Alberto, additional, Gutschalk, Alexander, additional, Schoenenberger, Silvia, additional, Nagel, Simon, additional, Buture, Alina, additional, Cervera, Alvaro, additional, Paiva Nunes, Ana, additional, Romina Montané Baños, Ana, additional, Tiede, Andreas, additional, Puthuppallil, Anemon, additional, Tuladhar, Anil M., additional, Mengel, Annerose, additional, Medina, Antonio, additional, Hellström Vogel, Åslög, additional, Tawa, Audrey, additional, Aujayeb, Avinash, additional, Ramasamy, Balakrishnan, additional, Casolla, Barbara, additional, Lim Alvin Chew, Beng, additional, Ziaadini, Bentalhoda, additional, Varkey Maramattom, Boby, additional, Buck, Brian, additional, Zanferrari, Carla, additional, Garcia-Esperon, Carlos, additional, Vayne, Caroline, additional, Legault, Catherine, additional, Jacobi, Christian, additional, Pfrepper, Christian, additional, Pelz, Johann, additional, Wahl, Christoph, additional, Kern, Rolf, additional, Tracol, Clement, additional, Soriano, Cristina, additional, Guisado-Alonso, Daniel, additional, Bougon, David, additional, Bal, Deepti, additional, Sergio Zimatore, Domenico, additional, Michalski, Dominik, additional, Blacquiere, Dylan, additional, Johansson, Elias, additional, Cuadrado-Godia, Elisa, additional, Sadeghi-Hokmabadi, Elyar, additional, Carrera, Emmanuel, additional, De Maistre, Emmanuel, additional, Saxhaug Kristoffersen, Espen, additional, Bonneville, Fabrice, additional, Geeraerts, Thomas, additional, Vuillier, Fabrice, additional, Giammello, Fabrizio, additional, D’Onofrio, Florindo, additional, Grillo, Francesco, additional, Caparros, François, additional, Susen, Sophie, additional, Maier, Frank, additional, Tsivgoulis, Georgios, additional, Gulli, Giosue, additional, Frisullo, Giovanni, additional, Franchineau, Guillaume, additional, Cangür, Hakan, additional, Katzberg, Hans, additional, Mozhdehipanah, Hossein, additional, Sibon, Igor, additional, Baharoglu, M. Irem, additional, Masjuan, Jaime, additional, Brar, Jaskiran, additional, Payen, Jean-Francois, additional, Burrow, Jim, additional, Fernandes, João, additional, Octavio López Esparza, Jorge, additional, Oen, Joyce, additional, Schouten, Judith, additional, Ng, Karl, additional, Chatterton, Sophie, additional, Wronski, Miriam, additional, Althaus, Katharina, additional, Garambois, Katia, additional, Derex, Laurent, additional, Puy, Laurent, additional, Poorsaadat, Leila, additional, Valler, Lenise, additional, Januzi de Almeida Rocha, Letícia, additional, Humbertjean, Lisa, additional, Lebrato Hernandez, Lucia, additional, Murillo-Bonilla, Luis, additional, Kellermair, Lukas, additional, Morin Martin, Mar, additional, Sofia Cotelli, Maria, additional, Hernandez Perez, Maria, additional, Zedde, Marialuisa, additional, Carvalho Dias, Mariana, additional, Dubois, Marie-Cecile, additional, Carvalho, Marta, additional, Ghiasian, Masoud, additional, Umaiorubahan, Meenakshisundaram, additional, Kumar Karunakaran, Ravi, additional, Roozbeh, Mehrdad, additional, Romoli, Michele, additional, Miranda, Miguel, additional, Saadatnia, Mohammad, additional, Bandettini di Poggio, Monica, additional, Scholz, Moritz J., additional, Kahnis, Robert, additional, Almasi-Dooghaee, Mostafa, additional, Hoseininejad Mir, Nahid, additional, Ichaporia, Nasli R., additional, Kumar Paramasivan, Naveen, additional, Erat Sreedharan, Sapna, additional, Sylaja, PN, additional, Raposo, Nicolas, additional, Fadakar, Nima, additional, Kruyt, Nyika, additional, Detante, Olivier, additional, Cuisenier, Pauline, additional, Huet, Olivier, additional, Sharma, Pankaj, additional, Candelaresi, Paolo, additional, Scoppettuolo, Pasquale, additional, Reiner, Peggy, additional, Nemati, Reza, additional, Vieira, Ricardo, additional, Goh, Rudy, additional, Murphy, Seán, additional, Timsit, Serge, additional, Coutts, Shelagh, additional, Sharma, Shyam S., additional, Bal, Simerpreet, additional, Kaul, Subhash, additional, Karapanayiotides, Theodoros, additional, Cox, Thomas, additional, Gattringer, Thomas, additional, Mathew, Thomas, additional, Bartsch, Thorsten, additional, Shaygannejad, Vahid, additional, Garcia-Talavera, Veronica, additional, Palma, Vincenzo, additional, Arslan, Yıldız, additional, Mirzaasgari, Zahra, additional, Yavari, Zeinab, additional, Zamani, Zohreh, additional, Bakchoul, Tamam, additional, Levi, Marcel, additional, and van Gorp, Eric C.M., additional

Published
2023
Full Text
View/download PDF

3. Cerebral venous sinus thrombosis due to vaccine-induced immune thrombotic thrombocytopenia in middle-income countries

Author

van de Munckhof, Anita, primary, Borhani-Haghighi, Afshin, additional, Aaron, Sanjith, additional, Krzywicka, Katarzyna, additional, van Kammen, Mayte Sánchez, additional, Cordonnier, Charlotte, additional, Kleinig, Timothy J, additional, Field, Thalia S, additional, Poli, Sven, additional, Lemmens, Robin, additional, Scutelnic, Adrian, additional, Lindgren, Erik, additional, Duan, Jiangang, additional, Arslan, Yıldız, additional, van Gorp, Eric CM, additional, Kremer Hovinga, Johanna A, additional, Günther, Albrecht, additional, Jood, Katarina, additional, Tatlisumak, Turgut, additional, Putaala, Jukka, additional, Heldner, Mirjam R, additional, Arnold, Marcel, additional, de Sousa, Diana Aguiar, additional, Wasay, Mohammad, additional, Arauz, Antonio, additional, Conforto, Adriana Bastos, additional, Ferro, José M, additional, Coutinho, Jonathan M, additional, Mbroh, Joshua, additional, Ciccone, Alfonso, additional, Wittstock, Matthias, additional, Zimmermann, Julian, additional, Bode, Felix J, additional, Skjelland, Mona, additional, Dizonno, Vanessa, additional, Devroye, Annemie, additional, Hiltunen, Sini, additional, Petruzzellis, Marco, additional, Bakchoul, Tamam, additional, Levi, Marcel, additional, Middeldorp, Saskia, additional, Sharma, Aarti R, additional, Ghoreishi, Abdoreza, additional, Elkady, Ahmed, additional, Negro, Alberto, additional, Gutschalk, Alexander, additional, Buture, Alina, additional, Cervera, Alvaro, additional, Paiva Nunes, Ana, additional, Romina Montané Baños, Ana, additional, Tiede, Andreas, additional, Tuladhar, Anil M, additional, Mengel, Annerose, additional, Medina, Antonio, additional, Aujayeb, Avinash, additional, Ramasamy, Balakrishnan, additional, Casolla, Barbara, additional, Spratt, Neil, additional, Ziaadini, Bentolhoda, additional, Varkey Maramattom, Boby, additional, Buck, Brian, additional, Garcia-Esperon, Carlos, additional, Vayne, Caroline, additional, Jacobi, Christian, additional, Pfrepper, Christian, additional, Bal, Deepti, additional, Sergio Zimatore, Domenico, additional, Michalski, Dominik, additional, Blacquiere, Dylan, additional, Johansson, Elias, additional, Cuadrado-Godia, Elisa, additional, Sadeghi-Hokmabadi, Elyar, additional, Carrera, Emmanuel, additional, Maistre, Emmanuel De, additional, Saxhaug Kristoffersen, Espen, additional, Hooshmandi, Etrat, additional, Bonneville, Fabrice, additional, Vuillier, Fabrice, additional, Giammello, Fabrizio, additional, D’Onofrio, Florindo, additional, Tsivgoulis, Georgios, additional, Gulli, Giosue, additional, Katzberg, Hans, additional, Sibon, Igor, additional, Baharoglu, Irem, additional, Masjuan, Jaime, additional, Fernandes, João, additional, Pelz, Johann, additional, Octavio López Esparza, Jorge, additional, Schouten, Judith, additional, Ng, Karl, additional, Derex, Laurent, additional, Puy, Laurent, additional, Poorsaadat, Leila, additional, Valler, Lenise, additional, Januzi de Almeida Rocha, Letícia, additional, Murillo-Bonilla, Luis, additional, Kellermair, Lukas, additional, Morin Martin, Mar, additional, Sofia Cotelli, Maria, additional, Hernandez Perez, Maria, additional, Zedde, Marialuisa, additional, Carvalho Dias, Mariana, additional, Carvalho, Marta, additional, Ghiasian, Masoud, additional, Umaiorubahan, Meenakshisundaram, additional, Roozbeh, Mehrdad, additional, Romoli, Michele, additional, Miranda, Miguel, additional, Wronski, Miriam, additional, Saadatnia, Mohammad, additional, Bandettini di Poggio, Monica, additional, Almasi-Dooghaee, Mostafa, additional, Hoseininejad Mir, Nahid, additional, Ichaporia, Nasli R, additional, Kumar Paramasivan, Naveen, additional, Raposo, Nicolas, additional, Fadakar, Nima, additional, Kruyt, Nyika, additional, Detante, Olivier, additional, Sharma, Pankaj, additional, Candelaresi, Paolo, additional, Scoppettuolo, Pasquale, additional, Reiner, Peggy, additional, Sylaja, PN, additional, Kumar Karunakaran, Ravi, additional, Vieira, Ricardo, additional, Kern, Rolf, additional, Goh, Rudy, additional, Erat Sreedharan, Sapna, additional, Murphy, Seán, additional, Timsit, Serge, additional, Coutts, Shelagh, additional, Sharma, Shyam S, additional, Schoenenberger, Silvia, additional, Nagel, Simon, additional, Kaul, Subhash, additional, Karapanayiotides, Theodoros, additional, Gattringer, Thomas, additional, Mathew, Thomas, additional, Bartsch, Thorsten, additional, Palma, Vincenzo, additional, Mirzaasgari, Zahra, additional, Zamani, Zohreh, additional, Mirahmadizadeh, Alireza, additional, Gutierrez-Romero, Alonso, additional, Iván Valdes-Ferrer, Ivan, additional, Elizabeth Ceballos-Liceaga, Santa, additional, and Maria Santibañez-Copado, Ana, additional

Published
2023
Full Text
View/download PDF

4. Thrombolysis after dabigatran reversal: A nation-wide Italian multicentre study, systematic review and meta-analysis

Author

Romoli, Michele, primary, Matteo, Eleonora, additional, Migliaccio, Ludovica, additional, Gentile, Mauro, additional, Mosconi, Maria Giulia, additional, Scura, Giuseppe Maria, additional, Naccarato, Marcello, additional, Colangeli, Enrico, additional, Candelaresi, Paolo, additional, Andreone, Vincenzo, additional, Giammello, Fabrizio, additional, Fortunata Musolino, Rosa, additional, Dell’Aera, Cristina, additional, Sepe, Federica Nicoletta, additional, Pronello, Edoardo, additional, Barbarini, Leonardo, additional, Caggiula, Marcella, additional, Rizzo, Federica, additional, Petruzzellis, Marco, additional, Giorli, Elisa, additional, Zedde, Maria Luisa, additional, Anticoli, Sabrina, additional, Mangiardi, Marilena, additional, Muto, Mario, additional, Diana, Francesco, additional, De Angelis, Maria Vittoria, additional, Digiovanni, Anna, additional, Concari, Letizia, additional, La Gioia, Sara, additional, Sessa, Maria, additional, Biguzzi, Sara, additional, Cordici, Francesco, additional, Longoni, Marco, additional, Ruggiero, Maria, additional, Cenciarelli, Silvia, additional, Eusebi, Paolo, additional, Sacco, Simona, additional, Caso, Valeria, additional, Paciaroni, Maurizio, additional, Ricci, Stefano, additional, Zini, Andrea, additional, Toni, Danilo, additional, and Giannandrea, David, additional

Published
2022
Full Text
View/download PDF

5. Real-world comparison of dual versus single antiplatelet treatment in patients with non-cardioembolic mild-to-moderate ischemic stroke: A propensity matched analysis.

Author

Foschi M, Ornello R, D'Anna L, De Matteis E, De Santis F, Barone V, Viola M, Mosconi MG, Rosin D, Romoli M, Tassinari T, Cenciarelli S, Censori B, Zedde M, Diomedi M, Petruzzellis M, Inchingolo V, Cappellari M, Candelaresi P, Bavaro A, Cavallini A, Piscaglia MG, Terruso V, Pezzini A, Frisullo G, Muscia F, Zini A, Leone R, Palmieri C, Cupini LM, Marcon M, Tassi R, Sanzaro E, Papiri G, Viticchi G, Orsucci D, Falcou A, Diamanti S, Tarletti R, Nencini P, Rota E, Sepe FN, Caputi L, Volpi G, La Spada S, Beccia M, Mastrangelo V, Invernizzi P, Pelliccioni G, De Angelis MV, Bonanni L, Ruzza G, Caggia EA, Russo M, Tonon A, Acciarri MC, Anticoli S, Roberti C, Scaglione G, Pistoia F, Alessi C, De Boni A, Sanna A, Chiti A, Barbarini L, Masato M, Del Sette M, Passarelli F, Bongioanni MR, De Michele M, Ricci S, Valente M, Gigli GL, Merlino G, Paciaroni M, Guarino M, and Sacco S

Abstract

Background: Short-term dual antiplatelet treatment (DAPT) is superior to single antiplatelet treatment (SAPT) for secondary prevention in non-cardioembolic minor ischemic stroke and high-risk transient ischemic attack (TIA). As the real-world use of DAPT is broader than in trials, it is important to clarify its benefit/risk profile in a diverse population., Methods: Post hoc analysis of prospectively collected data from the READAPT cohort and three prospective stroke registries including patients with mild-to-moderate (National Institute of Health Stroke Scale (NIHSS) score 0-10) ischemic stroke receiving early DAPT or SAPT. The primary effectiveness outcome was 90-day return to pre-stroke neurological functioning using modified Rankin Scale (mRS) score. Secondary effectiveness outcomes were 90-day mRS shift, new ischemic stroke/TIA, vascular and all-cause death, 24 h early neurological improvement or deterioration. The safety outcome was 90-day intracranial hemorrhage., Results: We matched 1008 patients treated with DAPT and 1008 treated with SAPT. Compared to SAPT, patients treated with DAPT showed higher likelihood of 90-day primary effectiveness outcome (87.5% vs. 84.4%, risk difference 3.1% (95% confidence interval (CI): 0.1%-6.1%); p = 0.047, risk ratio 1.03 (95% CI: 1.01-1.07); p = 0.043) and higher rate of 24-h early neurological improvement (25.3% vs. 15.4%, risk difference 9.9% (95% CI: 6.4%-13.4%); p < 0.001, risk ratio 1.65 (95% CI: 1.37-1.97); p < 0.001). No differences were observed for other study outcomes. Subgroup analysis confirmed benefit of DAPT over SAPT for primary effectiveness outcome in patients with moderate stroke, those treated with intravenous thrombolysis, and those who received antiplatelet loading dose., Conclusion: Our findings suggest that DAPT use might be safe and more effective than SAPT even in the real world and in patients who do not strictly fulfill the criteria of landmark large clinical trials., Competing Interests: Declaration of conflicting interestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: AZ reports compensation from Angels Initiative, Boehringer-Ingelheim, Daiichi Sankyo for consultant services; from Angels Initiative, Boehringer-Ingelheim, CSL Behring for speaking honoraria or other education services; from Daiichi Sankyo for meeting; from Bayer, and Astra Zeneca for participation on a Data Safety, Monitoring or Advisory Board; he is member of ESO guidelines, ISA-AII guidelines, and IRETAS steering committee. RO reports grants from Novartis and Allergan; compensation from Teva Pharmaceutical Industries, Eli Lilly and Company, and Novartis for other services; and travel support from Teva Pharmaceutical Industries. SS reports compensation from Novartis, NovoNordisk, Allergan, AstraZeneca, Pfizer Canada, Inc, Eli Lilly and Company, Teva Pharmaceutical Industries, H. Lundbeck A/S, and Abbott Canada for consultant services; compensation from Novartis for other services. MP reports compensation from Daiichi Sankyo Company, Bristol Myers Squibb, Bayer, and Pfizer Canada, Inc., for consultant services. The other authors report no conflicts.

Published
2024
Full Text
View/download PDF

6. Transient brain ischemic symptoms and the presence of ischemic lesions at neuroimaging: Results from the READAPT study.

Author

Ornello R, Foschi M, De Santis F, Romoli M, Tassinari T, Saia V, Cenciarelli S, Bedetti C, Padiglioni C, Censori B, Puglisi V, Vinciguerra L, Guarino M, Barone V, Zedde ML, Grisendi I, Diomedi M, Bagnato MR, Petruzzellis M, Mezzapesa DM, Di Viesti P, Inchingolo V, Cappellari M, Zenorini M, Candelaresi P, Andreone V, Rinaldi G, Bavaro A, Cavallini A, Moraru S, Querzani P, Terruso V, Mannino M, Scoditti U, Pezzini A, Frisullo G, Muscia F, Paciaroni M, Mosconi MG, Zini A, Leone R, Palmieri C, Cupini LM, Marcon M, Tassi R, Sanzaro E, Paci C, Viticchi G, Orsucci D, Falcou A, Diamanti S, Tarletti R, Nencini P, Rota E, Sepe FN, Ferrandi D, Caputi L, Volpi G, La Spada S, Beccia M, Rinaldi C, Mastrangelo V, Di Blasio F, Invernizzi P, Pelliccioni G, De Angelis MV, Bonanni L, Ruzza G, Caggia EA, Russo M, Tonon A, Acciarri MC, Anticoli S, Roberti C, Manobianca G, Scaglione G, Pistoia F, Fortini A, De Boni A, Sanna A, Chiti A, Barbarini L, Masato M, Del Sette M, Passarelli F, Bongioanni MR, Toni D, Ricci S, Sacco S, and De Matteis E

Abstract

Background: According to the literature, about one third of patients with brain ischemic symptoms lasting <24 h, which are classified as Transient ischemic attacks (TIAs) according to the traditional "time-based" definition, show the presence of acute ischemic lesions at neuroimaging. Recent evidence has shown that the presence of acute ischemic lesions at neuroimaging may impact on the outcome of patients with transient ischemic symptoms treated with dual antiplatelet treatment (DAPT). This uncertainty is even more compelling in recent years as short-term DAPT has become the standard treatment for any non-cardioembolic TIA or minor ischemic stroke., Methods: This is a pre-specified subgroup analysis from a prospective multicenter real-world study (READAPT). The analysis included patients with time-based TIA-that is, those with ischemic symptoms lasting <24 h-who started DAPT. In the whole population, we assessed the presence of acute brain ischemic lesions at neuroimaging and their association with the ABCD 2 score. To assess the impact of acute brain ischemic lesions on 90-day prognosis, we performed a propensity score matching of patients with and without those lesions. We adopted a primary effectiveness outcome which was a composite of new stroke/TIA events and death due to vascular causes at 90 days., Results: We included 517 patients-324 (62.7%) male-with a median (interquartile range-IQR) age of 74 (IQR = 65-81) years; 144 patients (27.9%) had acute brain ischemic lesions at neuroimaging. The proportion of patients with brain ischemic lesions did not vary according to the ABCD 2 score. At follow-up, 4 patients with brain ischemic lesions (2.8%) and 21 patients without lesions (5.6%) reported the primary effectiveness outcome, which was similar between the groups before ( p  = 0.178) and after matching ( p  = 0.518)., Conclusions: In our population, patients with transient ischemic symptoms and acute ischemic lesions at brain magnetic resonance imaging (MRI) had a risk of recurrent ischemic events similar to those without lesions. The risk of recurrent ischemic events was low in both groups., Competing Interests: Declaration of conflicting interestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: A.Z. reports compensation from Angels Initiative, Boehringer-Ingelheim, and Daiichi Sankyo for consultant services; from Angels Initiative, Boehringer-Ingelheim, and CSL Behring for speaking honoraria or other education services; from Daiichi Sankyo for meeting; from Bayer and Astra Zeneca for participation on a Data Safety, Monitoring Board or Advisory Board; and he is member of ESO guidelines, ISA-AII guidelines, and IRETAS steering committee. R.O. reports grants from Novartis and Allergan; compensation from Teva Pharmaceutical Industries, Eli Lilly and Company, and Novartis for other services; and travel support from Teva Pharmaceutical Industries. S.S. reports compensation from Novartis, NovoNordisk, Allergan, AstraZeneca, Pfizer Canada, Inc., Eli Lilly and Company, Teva Pharmaceutical Industries, H. Lundbeck A/S, and Abbott Canada for consultant services; employment by Università degli Studi dell’Aquila; and compensation from Novartis for other services. MP reports compensation from Daiichi Sankyo Company, Bristol Myers Squibb, Bayer, and Pfizer Canada, Inc., for consultant services. DT reports compensation from Alexion, Astra Zeneca, Medtronic, and Pfizer for consultant services and participation on a Data Safety, Monitoring Board or Advisory Board. The other authors report no conflicts.

Published
2024
Full Text
View/download PDF

7. Some minutes matter more: Groin-to-recanalization is the main time-related predictor of outcome in acute ischemic stroke.

Author

De Mase A, Spina E, Servillo G, Barbato S, Leone G, Giordano F, Renna R, Ranieri A, Iorio WD, Muto M, Guarnieri G, Muto M, Candelaresi P, and Andreone V

Abstract

Introduction: Endovascular thrombectomy (EVT) is the standard of care for selected patients with acute ischemic stroke (AIS) and large vessel occlusion (LVO), associated with intravenous thrombolysis, when indicated. While many studies focused on pre-hospital and in-hospital pathways, only few analyzed the relationship between groin-to-recanalization (GTR) time and functional outcome., Aim: To explore whether GTR time is an independent predictor of outcome in patients undergoing EVT., Methods: All patients with anterior circulation stroke treated with EVT at a high-volume center from January 2021 to December 2023 were included. The cohort was divided into two groups according to GTR time shorter or longer than 30 min. Regression analysis assessed the association between GTR time and 3-month good outcome, defined as modified Rankin Scale 0-2., Results: The study included 419 patients. The groups had similar baseline characteristics and similar onset to recanalization (OTR) time. Regression analysis showed shorter GTR time is an independent predictor of favorable outcome (OR 2.49 [95% CI 1.26-4.94]). Age, baseline NIHSS, ASPECT score and bridging IVT were also found to be independently associated with outcome., Discussion and Conclusions: Our study showed GTR time is an independent predictor of good outcome in patients undergoing EVT with similar OTR time, emphasizing procedural time as a key prognostic factor, even greater than other well-known pre-hospital and in-hospital time-dependent variables. These findings may raise the issue of developing alternative approaches or early "rescue" strategies for complicated procedures., Competing Interests: Declaration of conflicting interestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results